ACTRN12622000297729招募中未知
The Effect of Obesity on the Pharmacokinetic and Pharmacodynamic Disposition of Rivaroxaban in Patients with Venous Thromboembolism (VTE) or Non-valvular Atrial Fibrillation (AF)
Medical Research Center, Hamad Medical Corporation0 个研究点目标入组 81 人开始时间: 2022年2月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adults with age greater than or equal to 18 years
- •Diagnosis of DVT, PE, or non-valvular atrial fibrillation
- •Admission to medical ward or emergency department in Hamad General Hospital
- •Eligibility for rivaroxaban treatment
排除标准
- •Abnormal kidney function (CrCl of less than 30 ml/min)
- •Severe liver disease
- •Valvular heart disease
- •Hemodynamic instability or current admission to intensive care units
- •Active bleeding or high bleeding risk
- •Patients with extremely low weight (less than 50 kg)
- •Antiphospholipid antibody syndrome
- •Any other contraindications to rivaroxaban
研究者
相似试验
已完成
不适用
Effects of maternal obesity on the kinetic disposition of misoprostol during labor inductiomisoprostollabor inductionpharmacokineticsE04.520.252.968obesityRBR-7dq3v7bFaculdade de Medicina de Ribeirão Preto
已完成
1 期
A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese SubjectsMorbid ObesityNCT01591148Stanford University30
进行中（未招募）
不适用
Farmacocinética en la obesidad mórbida: estudio de la influencia de dos técnicas de cirugía bariátrica (bypass Gástrico y Sleeve Gastrectomy) en el metabolismo de fármacos.Obesidad mórbidaEUCTR2009-013156-72-ESIMAS
已完成
不适用
Effect of the anti-obesity mixture in metabolic-syndrome : a randomized controlled trialMetabolic-syndromeJPRN-UMIN000020929GMC Ltd.20
已完成
1 期
Pharmacokinetics in Morbid Obesity After Bariatric SurgeryMorbid ObesityOverweightNCT01086722Fundacion IMIM52